Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Pan-cancer whole-genome analyses of metastatic solid tumours.

Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, Duyvesteyn K, Haidari S, van Hoeck A, Onstenk W, Roepman P, Voda M, Bloemendal HJ, Tjan-Heijnen VCG, van Herpen CML, Labots M, Witteveen PO, Smit EF, Sleijfer S, Voest EE, Cuppen E.

Nature. 2019 Nov;575(7781):210-216. doi: 10.1038/s41586-019-1689-y. Epub 2019 Oct 23.

PMID:
31645765
2.

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.

Ooft SN, Weeber F, Dijkstra KK, McLean CM, Kaing S, van Werkhoven E, Schipper L, Hoes L, Vis DJ, van de Haar J, Prevoo W, Snaebjornsson P, van der Velden D, Klein M, Chalabi M, Boot H, van Leerdam M, Bloemendal HJ, Beerepoot LV, Wessels L, Cuppen E, Clevers H, Voest EE.

Sci Transl Med. 2019 Oct 9;11(513). pii: eaay2574. doi: 10.1126/scitranslmed.aay2574.

PMID:
31597751
3.

The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies.

Angus L, Smid M, Wilting SM, van Riet J, Van Hoeck A, Nguyen L, Nik-Zainal S, Steenbruggen TG, Tjan-Heijnen VCG, Labots M, van Riel JMGH, Bloemendal HJ, Steeghs N, Lolkema MP, Voest EE, van de Werken HJG, Jager A, Cuppen E, Sleijfer S, Martens JWM.

Nat Genet. 2019 Oct;51(10):1450-1458. doi: 10.1038/s41588-019-0507-7. Epub 2019 Sep 30.

PMID:
31570896
4.

Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands.

Westgeest HM, Kuppen MCP, van den Eertwegh AJM, de Wit R, Coenen JLLM, van den Berg HPP, Mehra N, van Oort IM, Fossion LMCL, Hendriks MP, Bloemendal HJ, van de Luijtgaarden ACM, Ten Bokkel Huinink D, van den Bergh ACMF, van den Bosch J, Polee MB, Weijl N, Bergman AM, Uyl-de Groot CA, Gerritsen WR.

Clin Genitourin Cancer. 2019 Oct;17(5):e946-e956. doi: 10.1016/j.clgc.2019.05.018. Epub 2019 May 31.

PMID:
31439536
5.

Screening and Stepped Care Targeting Psychological Distress in Patients With Metastatic Colorectal Cancer: The TES Cluster Randomized Trial.

Schuurhuizen CSEW, Braamse AMJ, Beekman ATF, Cuijpers P, van der Linden MHM, Hoogendoorn AW, Berkhof H, Sommeijer DW, Lustig V, Vrijaldenhoven S, Bloemendal HJ, van Groeningen CJ, van Zweeden AA, van der Vorst MJDL, Rietbroek R, Tromp-van Driel CS, Wymenga MNW, van der Linden PW, Beeker A, Polee MB, Batman E, Los M, van Bochove A, Brakenhoff JAC, Konings IRHM, Verheul HMW, Dekker J.

J Natl Compr Canc Netw. 2019 Aug 1;17(8):911-920. doi: 10.6004/jnccn.2019.7285.

PMID:
31390590
6.

Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone.

Bouman-Wammes EW, de Klerk JMH, Bloemendal HJ, Van Dodewaard-de Jong JM, Lange R, Ter Heine R, Verheul HMW, Van den Eertwegh AJM.

Clin Genitourin Cancer. 2019 Apr;17(2):e281-e292. doi: 10.1016/j.clgc.2018.11.014. Epub 2018 Nov 17. Review.

PMID:
30555024
7.

The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy.

Schuurhuizen CS, Verheul HM, Braamse AM, Buffart LM, Bloemendal HJ, Dekker J, Konings IR.

Cancer Manag Res. 2018 Aug 29;10:3015-3021. doi: 10.2147/CMAR.S166468. eCollection 2018.

8.

Four-year effects of exercise on fatigue and physical activity in patients with cancer.

Witlox L, Hiensch AE, Velthuis MJ, Steins Bisschop CN, Los M, Erdkamp FLG, Bloemendal HJ, Verhaar M, Ten Bokkel Huinink D, van der Wall E, Peeters PHM, May AM.

BMC Med. 2018 Jun 8;16(1):86. doi: 10.1186/s12916-018-1075-x.

9.

Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids.

van der Velden DL, Cirkel GA, Houthuijzen JM, van Werkhoven E, Roodhart JML, Daenen LGM, Kaing S, Gerrits J, Verhoeven-Duif NM, Grootscholten C, Boot H, Sessa C, Bloemendal HJ, De Vos FY, Voest EE.

Cancer Chemother Pharmacol. 2018 May;81(5):911-921. doi: 10.1007/s00280-018-3563-2. Epub 2018 Mar 24.

PMID:
29574584
10.

Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands.

Ter Heine R, Frederix GW, Geenen JW, Hövels AM, van Vulpen M, Kooistra A, De Klerk JM, Bloemendal HJ.

J Comp Eff Res. 2017 Oct;6(7):575-581. doi: 10.2217/cer-2017-0026. Epub 2017 Sep 13.

PMID:
29091013
11.

Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.

Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA, de Wit R, van den Bergh ACM, Coenen JLLM, Beerlage HP, Hendriks MP, Bos MMEM, van den Berg P, van de Wouw AJ, Spermon R, Boerma MO, Geenen MM, Tick LW, Polee MB, Bloemendal HJ, Cordia I, Peters FPJ, de Vos AI, van den Bosch J, van den Eertwegh AJM, Gerritsen WR.

Eur Urol Focus. 2018 Sep;4(5):694-701. doi: 10.1016/j.euf.2016.09.008. Epub 2016 Oct 13.

PMID:
28753794
12.

Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative.

Coebergh van den Braak RRJ, van Rijssen LB, van Kleef JJ, Vink GR, Berbee M, van Berge Henegouwen MI, Bloemendal HJ, Bruno MJ, Burgmans MC, Busch ORC, Coene PPLO, Coupé VMH, Dekker JWT, van Eijck CHJ, Elferink MAG, Erdkamp FLG, van Grevenstein WMU, de Groot JWB, van Grieken NCT, de Hingh IHJT, Hulshof MCCM, Ijzermans JNM, Kwakkenbos L, Lemmens VEPP, Los M, Meijer GA, Molenaar IQ, Nieuwenhuijzen GAP, de Noo ME, van de Poll-Franse LV, Punt CJA, Rietbroek RC, Roeloffzen WWH, Rozema T, Ruurda JP, van Sandick JW, Schiphorst AHW, Schipper H, Siersema PD, Slingerland M, Sommeijer DW, Spaander MCW, Sprangers MAG, Stockmann HBAC, Strijker M, van Tienhoven G, Timmermans LM, Tjin-A-Ton MLR, van der Velden AMT, Verhaar MJ, Verkooijen HM, Vles WJ, de Vos-Geelen JMPGM, Wilmink JW, Zimmerman DDE, van Oijen MGH, Koopman M, Besselink MGH, van Laarhoven HWM; Dutch Pancreatic Cancer Group, Dutch Upper GI Cancer Group and PLCRC working group.

Acta Oncol. 2018 Feb;57(2):195-202. doi: 10.1080/0284186X.2017.1346381. Epub 2017 Jul 19.

PMID:
28723307
13.

Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT).

Ubink I, Bloemendal HJ, Elias SG, Brink MA, Schwartz MP, Holierhoek YCW, Verheijen PM, Boerman AW, Mathijssen RHJ, de Leng WWJ, de Weger RA, van Grevenstein WMU, Koopman M, Lolkema MP, Kranenburg O, Borel Rinkes IHM.

BMC Cancer. 2017 Apr 19;17(1):282. doi: 10.1186/s12885-017-3264-y.

14.

A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.

van Dodewaard-de Jong JM, de Klerk JMH, Bloemendal HJ, Oprea-Lager DE, Hoekstra OS, van den Berg HP, Los M, Beeker A, Jonker MA, O'Sullivan JM, Verheul HMW, van den Eertwegh AJM.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1319-1327. doi: 10.1007/s00259-017-3673-9. Epub 2017 Apr 18.

PMID:
28421240
15.

Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.

Janssen A, Verkleij CPM, van der Vlist A, Mathijssen RHJ, Bloemendal HJ, Ter Heine R.

Br J Cancer. 2017 May 9;116(10):1312-1317. doi: 10.1038/bjc.2017.91. Epub 2017 Apr 11.

16.

Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: the randomised PACT study.

May AM, Bosch MJ, Velthuis MJ, van der Wall E, Steins Bisschop CN, Los M, Erdkamp F, Bloemendal HJ, de Roos MA, Verhaar M, Ten Bokkel Huinink D, Peeters PH, de Wit GA.

BMJ Open. 2017 Mar 6;7(3):e012187. doi: 10.1136/bmjopen-2016-012187.

17.

A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial.

van Dodewaard-de Jong JM, Bouman-Wammes EW, Bloemendal HJ, Verheul HMW, de Klerk JMH, van den Eertwegh AJM.

Clin Nucl Med. 2017 Jun;42(6):415-420. doi: 10.1097/RLU.0000000000001604.

PMID:
28263212
18.

Cytotoxic Effects of the Therapeutic Radionuclide Rhenium-188 Combined with Taxanes in Human Prostate Carcinoma Cell Lines.

Lange R, ter Heine R, van Wieringen WN, Tromp AM, Paap M, Bloemendal HJ, de Klerk JM, Hendrikse NH, Geldof AA.

Cancer Biother Radiopharm. 2017 Feb;32(1):16-23. doi: 10.1089/cbr.2016.2129. Epub 2017 Jan 24.

PMID:
28118029
19.

Erratum to "Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases" [Bone 91 (2016) 159-179].

Lange R, Ter Heine R, Knapp RF, de Klerk JMH, Bloemendal HJ, Hendrikse HN.

Bone. 2017 Dec;105:315. doi: 10.1016/j.bone.2016.11.023. Epub 2016 Nov 30. No abstract available.

PMID:
27914925
20.

Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases.

Lange R, Ter Heine R, Knapp RF, de Klerk JM, Bloemendal HJ, Hendrikse NH.

Bone. 2016 Oct;91:159-79. doi: 10.1016/j.bone.2016.08.002. Epub 2016 Aug 2. Review. Erratum in: Bone. 2017 Dec;105:315.

PMID:
27496068
21.

Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.

Lange R, Overbeek F, de Klerk JM, Pasker-de Jong PC, van den Berk AM, Ter Heine R, Rodenburg CJ, Kooistra A, Hendrikse NH, Bloemendal HJ.

Nuklearmedizin. 2016 Sep 26;55(5):188-95. doi: 10.3413/Nukmed-0828-16-05. Epub 2016 Jul 22.

PMID:
27443809
22.

Effects of an Exercise Program in Colon Cancer Patients undergoing Chemotherapy.

Van Vulpen JK, Velthuis MJ, Steins Bisschop CN, Travier N, Van Den Buijs BJ, Backx FJ, Los M, Erdkamp FL, Bloemendal HJ, Koopman M, De Roos MA, Verhaar MJ, Ten Bokkel-Huinink D, Van Der Wall E, Peeters PH, May AM.

Med Sci Sports Exerc. 2016 May;48(5):767-75. doi: 10.1249/MSS.0000000000000855.

PMID:
26694846
23.

Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.

Jong JM, Oprea-Lager DE, Hooft L, de Klerk JM, Bloemendal HJ, Verheul HM, Hoekstra OS, van den Eertwegh AJ.

Eur Urol. 2016 Sep;70(3):416-26. doi: 10.1016/j.eururo.2015.09.005. Epub 2015 Sep 19. Review.

PMID:
26391636
24.

Effects of an 18-week exercise programme started early during breast cancer treatment: a randomised controlled trial.

Travier N, Velthuis MJ, Steins Bisschop CN, van den Buijs B, Monninkhof EM, Backx F, Los M, Erdkamp F, Bloemendal HJ, Rodenhuis C, de Roos MA, Verhaar M, ten Bokkel Huinink D, van der Wall E, Peeters PH, May AM.

BMC Med. 2015 Jun 8;13:121. doi: 10.1186/s12916-015-0362-z.

25.

New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?

van Dodewaard-de Jong JM, Verheul HMW, Bloemendal HJ, de Klerk JMH, Carducci MA, van den Eertwegh AJM.

Clin Genitourin Cancer. 2015 Aug;13(4):271-279. doi: 10.1016/j.clgc.2015.01.008. Epub 2015 Jan 21. Review.

PMID:
25704270
26.

Drug composition matters: the influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188Rhenium-HEDP.

Lange R, de Klerk JMH, Bloemendal HJ, Ramakers RM, Beekman FJ, van der Westerlaken MML, Hendrikse NH, Ter Heine R.

Nucl Med Biol. 2015 May;42(5):465-469. doi: 10.1016/j.nucmedbio.2015.01.007. Epub 2015 Jan 22.

PMID:
25662844
27.

Metastatic Prostate Cancer and Skeletal Related Events, a Cost of Illness Study.

Geenen JW, Heine Ter R, Frederix GW, Hövels A, Vulpen van M, Kooistra A, Klerk de JM, Bloemendal HJ.

Value Health. 2014 Nov;17(7):A626. doi: 10.1016/j.jval.2014.08.2229. Epub 2014 Oct 26. No abstract available.

28.

Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.

ter Heine R, Lange R, Breukels OB, Bloemendal HJ, Rummenie RG, Wakker AM, de Graaf H, Beekman FJ, van der Westerlaken MM, Malingré MM, Wielders JP, van den Berg L, Hendrikse NH, de Klerk JM.

Int J Pharm. 2014 Apr 25;465(1-2):317-24. doi: 10.1016/j.ijpharm.2014.01.034. Epub 2014 Feb 19.

PMID:
24560635
29.

Severe hypertriglyceridaemia associated with the use of capecitabine.

Polinder-Bos HA, Kok EE, van de Wiel A, Spiering W, Wielders JP, Bloemendal HJ.

Neth J Med. 2012 Mar;70(2):104. No abstract available.

30.

A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).

van Dodewaard-de Jong JM, de Klerk JM, Bloemendal HJ, van Bezooijen BP, de Haas MJ, Wilson RH, O'Sullivan JM.

Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):1990-8. doi: 10.1007/s00259-011-1883-0. Epub 2011 Jul 27.

PMID:
21792569
31.

Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.

Kroep JR, Linn SC, Boven E, Bloemendal HJ, Baas J, Mandjes IA, van den Bosch J, Smit WM, de Graaf H, Schröder CP, Vermeulen GJ, Hop WC, Nortier JW.

Neth J Med. 2010 Sep;68(9):371-6.

32.

Activated vitronectin as a target for anticancer therapy with human antibodies.

Bloemendal HJ, de Boer HC, Koop EA, van Dongen AJ, Goldschmeding R, Landman WJ, Logtenberg T, Gebbink MF, Voest EE.

Cancer Immunol Immunother. 2004 Sep;53(9):799-808. Epub 2004 Jun 10.

PMID:
15197494
33.

Fibrin-incorporated vitronectin is involved in platelet adhesion and thrombus formation through homotypic interactions with platelet-associated vitronectin.

Wu YP, Bloemendal HJ, Voest EE, Logtenberg T, de Groot PG, Gebbink MF, de Boer HC.

Blood. 2004 Aug 15;104(4):1034-41. Epub 2004 Apr 6.

PMID:
15069014
34.

[Cerebral infarction and myocardial infarction due to cisplatin-containing chemotherapy].

Brouha ME, Bloemendal HJ, Kappelle LJ, Winter JB.

Ned Tijdschr Geneeskd. 2003 Mar 8;147(10):457-60. Dutch. Erratum in: Ned Tijdschr Geneeskd. 2003 Dec 27;147(52):2612.

PMID:
12666519
35.

New strategies in anti-vascular cancer therapy.

Bloemendal HJ, Logtenberg T, Voest EE.

Eur J Clin Invest. 1999 Sep;29(9):802-9. Review.

PMID:
10469169
36.

Hyperamylasaemia in multiple myeloma.

Bloemendal HJ, Lobatto S.

Neth J Med. 1996 Jul;49(1):38-41.

PMID:
8772359

Supplemental Content

Loading ...
Support Center